Nuvalent Inc.
GSK to Acquire Nuvalent for $10.6 Billion in Oncology Deal
Summary
Nuvalent, Inc., a clinical-stage biopharmaceutical company, has entered into an Agreement and Plan of Merger with GSK, whereby GSK will acquire all outstanding shares of Nuvalent for $124 per share in cash, totaling approximately $10.6 billion. The acquisition includes three products targeting lung cancer, two of which are under FDA review with potential approvals in 2026. The transaction is expected to be accretive to GSK's sales and core operating profit from 2027 and core EPS in 2029, inclusive of synergies and reprioritization. The deal is subject to customary closing conditions, including the tender of a majority of Nuvalent's shares and regulatory approvals.
Profitelligence Alerts
Get alerts for NUVL
Be first to know when Nuvalent Inc. files with the SEC.
Filing Categories
Advertisement
About Nuvalent Inc.
Nuvalent Inc. is a biopharmaceutical company dedicated to the innovative development of small molecule therapies for cancer treatment. The company's primary focus is on creating targeted solutions for patients with cancer-related resistance mutations and treatment-related adverse effects. By leveraging their expertise in medicinal chemistry and deep understanding of tumor biology, Nuvalent aims to address significant gaps in current cancer therapies, particularly where existing treatments fall short due to resistance mechanisms. The company operates in a highly specialized sector that covers oncology research and development, presenting potential game-changing approaches within the broader pharmaceutical industry. Through its commitment to research and innovation, Nuvalent collaborates with leading research institutions to push the boundaries of what is achievable in cancer treatment. Situated within an ever-evolving market, the company plays a critical role in advancing new oncological solutions that may ultimately improve the quality of life for patients globally. Founded with the mission to transform patient care, Nuvalent's asset offerings are a testament to the progressive strides being made in next-generation cancer therapeutics.
Official SEC Documents
Advertisement